Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference14 articles.
1. Projections of global mortality and burden of disease from 2002 to 2030;Mathers;PLoS Med,2006
2. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey;Zhong;Am J Respir Crit Care Med,2007
3. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population;Menzin;Respir Med,2008
4. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma;Field;Expert Opin Investig Drugs,2008
5. Roflumilast: systemic therapy for COPD;McIvor;Expert Rev Respir Med,2010
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Analysis of Tiotropium bromide and Roflumilast: Two Potent Medications for Chronic Obstructive Pulmonary Disease;2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences;2022-10-13
2. Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis;Cureus;2022-03-04
3. The PI3K/AKT/mTOR pathway regulates autophagy to induce apoptosis of alveolar epithelial cells in chronic obstructive pulmonary disease caused by PM2.5 particulate matter;Journal of International Medical Research;2020-07
4. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease;Cochrane Database of Systematic Reviews;2020-05-01
5. Efficacy and safety profile of roflumilast in a real-world experience;Journal of Thoracic Disease;2019-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3